Skip to main content

Advertisement

Table 1 Clinical characteristics of the discovery cohort

From: Random forest-based modelling to detect biomarkers for prostate cancer progression

  Good prognosisa Poor prognosisa
n 35 35
Age (mean ± sd) 62.7 ± 5.6 65 ± 6.6
Pretreatment PSA (ng/ml) 6.86 ± 3.4 28.3 ± 22.3
Stage (path. T)
 pT2 35 0
 pT3a 0 3
 pT3b 0 31
 pT4 0 1
Gleason score
 3 + 3 15 0
 3 + 4 17 6
 4 + 3 3 15
 4 + 4 0 4
 4 + 5 0 7
 5 + 4 0 3
  1. aGood prognosis defined as an organ-confined disease (pT2) and lack of biochemical (PSA-based) recurrence (BCR) for at least 5 years. Poor prognosis defined as systemic presence of metastatic disease, indicated by recurrence within 3 years and no response to local radiation therapy